Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K H Moore

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Journal of Clinical Pharmacology|June 4, 1999
Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorptionK H Moore, S Shaw, A L Laurent, et al.
American Journal of Obstetrics and Gynecology|December 16, 1997
The fetoplacental pressor effects of low-dose acetylsalicylic acid and angiotensin II in the ex vivo cotyledon modelP G Napolitano, N J Hoeldtke, K H Moore, et al.
AIDS (London, England)|November 24, 1999
The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1K H Moore, J E Barrett, S Shaw, et al.
Cancer Research|May 1, 1988
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancerP M Sondel, P C Kohler, J A Hank, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1995
Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062)K H Moore, R H Raasch, K L Brouwer, et al.
HIV Clinical Trials|October 9, 2001
GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudineK Arasteh, R Wood, M Müller, et al.
Journal of Biological Response Modifiers|April 1, 1988
The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2N S Rosenthal, J A Hank, P C Kohler, et al.
Cancer Research|March 15, 1993
A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humansJ H Schiller, J Hank, B Storer, et al.
Cancer Research|December 1, 1989
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activityD Goldstein, J A Sosman, J A Hank, et al.
Cancer Research|April 1, 1988
In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2J A Hank, P C Kohler, G Weil-Hillman, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Journal of Clinical Pharmacology|June 4, 1999
Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorptionK H Moore, S Shaw, A L Laurent, et al.
American Journal of Obstetrics and Gynecology|December 16, 1997
The fetoplacental pressor effects of low-dose acetylsalicylic acid and angiotensin II in the ex vivo cotyledon modelP G Napolitano, N J Hoeldtke, K H Moore, et al.
AIDS (London, England)|November 24, 1999
The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1K H Moore, J E Barrett, S Shaw, et al.
Cancer Research|May 1, 1988
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancerP M Sondel, P C Kohler, J A Hank, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1995
Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062)K H Moore, R H Raasch, K L Brouwer, et al.
HIV Clinical Trials|October 9, 2001
GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudineK Arasteh, R Wood, M Müller, et al.
Journal of Biological Response Modifiers|April 1, 1988
The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2N S Rosenthal, J A Hank, P C Kohler, et al.
Cancer Research|March 15, 1993
A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humansJ H Schiller, J Hank, B Storer, et al.
Cancer Research|December 1, 1989
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activityD Goldstein, J A Sosman, J A Hank, et al.
Cancer Research|April 1, 1988
In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2J A Hank, P C Kohler, G Weil-Hillman, et al.
Pageof 11